Thrivent Financial for Lutherans Has $13.34 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Thrivent Financial for Lutherans cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 75.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 233,016 shares of the biopharmaceutical company's stock after selling 709,813 shares during the quarter. Thrivent Financial for Lutherans owned 0.18% of Halozyme Therapeutics worth $13,337,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of HALO. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in Halozyme Therapeutics during the second quarter worth $49,000. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $65,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded up $3.30 during midday trading on Friday, hitting $49.00. The stock had a trading volume of 4,549,535 shares, compared to its average volume of 1,368,916. The company's 50-day moving average price is $54.85 and its 200-day moving average price is $53.42. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $6.23 billion, a P/E ratio of 16.18, a price-to-earnings-growth ratio of 0.41 and a beta of 1.29.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 60,000 shares of company stock worth $3,425,000 over the last three months. Insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Benchmark reiterated a "buy" rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. HC Wainwright restated a "buy" rating and set a $68.00 target price on shares of Halozyme Therapeutics in a report on Wednesday. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price target for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.